JFL Life Sciences Ltd
₹ 10.8
2.38%
11 Mar
- close price
About
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
Key Points
- Market Cap ₹ 70.9 Cr.
- Current Price ₹ 10.8
- High / Low ₹ 21.2 / 9.54
- Stock P/E 14.7
- Book Value ₹ 6.39
- Dividend Yield 0.00 %
- ROCE 15.8 %
- ROE 11.1 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 174 days to 124 days
Cons
- Company has a low return on equity of 11.0% over last 3 years.
- Company has high debtors of 155 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 31.78 | 30.17 | 32.77 | 33.59 | 42.83 | 46.55 | 82.04 | 80.07 | |
| 30.45 | 28.31 | 30.61 | 28.23 | 38.91 | 41.96 | 73.84 | 70.50 | |
| Operating Profit | 1.33 | 1.86 | 2.16 | 5.36 | 3.92 | 4.59 | 8.20 | 9.57 |
| OPM % | 4.19% | 6.17% | 6.59% | 15.96% | 9.15% | 9.86% | 10.00% | 11.95% |
| 0.00 | 0.03 | 0.09 | 0.89 | 1.64 | 0.51 | 0.01 | 0.02 | |
| Interest | 0.75 | 1.16 | 1.23 | 2.08 | 1.42 | 0.86 | 1.08 | 1.39 |
| Depreciation | 0.15 | 0.24 | 0.28 | 0.37 | 0.43 | 0.44 | 0.99 | 1.16 |
| Profit before tax | 0.43 | 0.49 | 0.74 | 3.80 | 3.71 | 3.80 | 6.14 | 7.04 |
| Tax % | 27.91% | 28.57% | 27.03% | 26.05% | 24.53% | 13.16% | 32.25% | |
| 0.30 | 0.36 | 0.54 | 2.81 | 2.81 | 3.30 | 4.16 | 4.82 | |
| EPS in Rs | 1.25 | 1.50 | 1.50 | 0.59 | 0.43 | 0.50 | 0.63 | 0.73 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.33% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 35% |
| TTM: | -13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 63% |
| 3 Years: | 14% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.50 | 8.02 | 11.00 | 11.00 | 33.00 | 33.00 |
| Reserves | 4.59 | 4.95 | 6.38 | 3.27 | 21.27 | 24.58 | 6.46 | 9.19 |
| 8.41 | 9.33 | 16.82 | 15.85 | 7.18 | 5.69 | 10.59 | 11.20 | |
| 2.73 | 9.63 | 5.31 | 21.12 | 9.60 | 15.44 | 21.86 | 32.19 | |
| Total Liabilities | 16.15 | 24.33 | 29.01 | 48.26 | 49.05 | 56.71 | 71.91 | 85.58 |
| 2.48 | 5.05 | 6.50 | 7.13 | 6.80 | 12.47 | 12.24 | 11.80 | |
| CWIP | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13.63 | 19.28 | 22.51 | 41.13 | 42.25 | 44.24 | 59.67 | 73.78 | |
| Total Assets | 16.15 | 24.33 | 29.01 | 48.26 | 49.05 | 56.71 | 71.91 | 85.58 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -3.00 | 3.21 | -5.87 | 2.32 | -9.07 | 8.41 | -3.53 | |
| -0.61 | -2.76 | -1.64 | -0.71 | 0.87 | -6.09 | -0.01 | |
| 3.61 | -0.19 | 7.25 | -1.46 | 8.07 | -2.35 | 3.54 | |
| Net Cash Flow | 0.00 | 0.27 | -0.26 | 0.15 | -0.13 | -0.03 | 0.00 |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 110.95 | 153.16 | 131.54 | 215.15 | 191.58 | 202.69 | 155.49 |
| Inventory Days | 21.43 | 51.75 | 72.47 | 211.64 | 130.01 | 144.63 | 128.31 |
| Days Payable | 17.79 | 121.71 | 57.70 | 218.43 | 75.53 | 114.30 | 98.05 |
| Cash Conversion Cycle | 114.58 | 83.20 | 146.31 | 208.36 | 246.06 | 233.02 | 185.75 |
| Working Capital Days | 62.36 | 6.90 | 74.07 | 116.60 | 221.23 | 176.66 | 123.77 |
| ROCE % | 11.74% | 10.26% | 23.13% | 15.41% | 11.55% | 15.81% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Revenue from Operations Growth percentage |
|
|||
| Trade Receivable Turnover Ratio ratio |
||||
| Number of New Pharma Products Launched (Domestic) number |
||||
| Specific Order: J D Healthcare (Pharma Supply) INR Crores |
||||
| Specific Order: Phil Capital Trading Solutions Inc (International Capsule Manufacturing) USD Millions |
||||
| Total Permanent Employees number |
||||
Requires Premium
Requires Premium
Documents
Announcements
-
Updates
4 March 2026 - 1:1 rights issue of 3,29,95,323 shares at Rs10, raising Rs32.9953 crore; opens 16–24 Mar 2026.
-
Record Date
4 March 2026 - Record date March 10, 2026 for 1:1 fully paid rights issue to shareholders.
-
Rights Issue
4 March 2026 - Approves 1:1 rights issue of 3,29,95,323 shares at Rs10; opens Mar 16, closes Mar 24, 2026.
-
Outcome of Board Meeting
29 January 2026 - Board approved unaudited financial results for quarter and nine months ended Dec 31, 2025; limited review attached.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
5 January 2026 - Certificate under Reg 74(5) by KFIN for quarter Oct 1–Dec 31, 2025.
Business Overview:[1]
JFLLSL is a WHO-GMP Certified pharmaceutical company that manufactures and sells products across multiple markets. It specializes in Dry Powder Injectable Solid Oral Dosage Forms (Beta-Lactam & General)